Facebook Twitter Instagram

(917) 985-3400

Contact Us

INNOVATIVE CANCER CARE

About Verthermia®

At Verthermia®, our mission is to extend and enhance life for people with advanced unresponsive cancer. We also pledge to continue investigating how our natural process can fight deadly diseases and viruses, in addition to cancer treatment. Through our perseverance and motivation, we vow to always provide safe, effective treatment and minimize side effects.
Get Started

OVERSEEING OPERATIONS

Our Management Team

Verthermia’s management team is responsible for overseeing all medical operations and ensuring that our treatment protocols are in line with the latest advancements in the field. Our team is composed of professionals from the medical and business worlds. Working in tandem with our staff of highly trained professionals, our management team provides the foundation for Verthermia’s operational and medical efficiency.

Roger Vertrees, Ph.D.

Chief Science Officer

Roger is a Certified Clinical Perfusionist Emeritus, and he received his Ph.D. from the University of Texas in Biomedical Sciences with a concentration in Experimental Oncologic Pathology. He retired from University of Texas Medical Branch as Associate Professor of Surgery. He currently focuses all his time and energy into ®Verthermia and is the developer and innovator of the HEATT circuit and technology. Roger has more than 30 years of research in whole-body hyperthermia and Roger has conducted all preclinical animal studies in hyperthermia and all of the human trials of lung and ovarian cancer patients.

GUIDING OUR RESEARCH

Our Board of Directors

Our board of directors consists of passionate, dedicated individuals with a wealth of experience in the areas of cancer and hyperthermia treatments. We are proud to have a diverse board that provides insight into various aspects of cancer care. They are integral to our mission of providing patients with exceptional treatment.

CANCER SPECIALISTS

Our Medical Advisory Board

Marek Stubley

Board Member, Consultant

Mr. Marek Stubley is a Founding Partner at the highly specialized boutique law firm in Prague of A3K. A3K caters to a select group of successful executives and corporate clientile. Mr. Stubley handles a specialized group of clients in the areas of: private equity; real estate; hospitals; and entertainment. He has overseen complex litigations in the European Union and in the United States. He is a lifelong devoted cyclist and skier. His passion for cycling and skiing is only surpassed for his love of his daughter and son, whom he and his wife, Tereza, are proudly raising outside of Prague. Marek brings to Verthermia a strong desire to help expand the company’s operations outside of the United States to Europe. He was also recruited to help facilitate the company accessing both capital markets and private equity globally.

Our Medical Advisory Board

Combining cutting-edge technology with evidence-based treatment, the medical advisory board at Verthermia includes top minds of cancer treatment. Our team is composed of experienced specialists and scientists who are committed to helping our patients achieve positive outcomes. Collectively, they bring a wealth of knowledge and experience to the table, allowing us to stay ahead of emerging trends in hyperthermia cancer treatment.
Jay-Smith
Dennis-Chi-M.D
Jan-Winetz-MD
James-Cusack-M.D
Joseph-Jay-B.-Zwischenberger-MD-FACS-1
Mitchel-K.-May-JD
David-Bartlett-M.D
Robert-DeBernardo-M.D.
Daniel-Labow-M.D.
Gary-Keeling
Roger-Vertrees-PHD
Joseph-Jay-B.-Zwischenberger-MD-FACS
Ray-Stapleton
Paul-J.-Manafort-1
petra-1
Dennis-Chi-M.D
PHOTO-2023-03-19-04-03-44

James Cusack, M.D

Gastrointestinal Surgeon, Colorectal Surgeon

Dr. Cusack serves on the Harvard Medical School faculty, Massachusetts General staff, and the consulting staff at Dana-Farber Cancer Institute. At Massachusetts General, Dr. Cusack is the Director of the Peritoneal Surface Malignancy (HIPEC) Program and Surgical Oncology Laboratories. He was additionally Chair of the SSO Scientific Program Committee and served on the Executive Council of the Society of Surgical Oncology (SSO).

DATA-DRIVEN TREATMENT

Clinical Trial Results

At Verthermia®, we believe that everyone should have access to effective cancer treatments and strive to provide our clients with the best care possible. We are committed to continuing research on whole-body hyperthermia so that we can provide the latest information on its efficacy in treating cancer. Our team has conducted clinical trials, which to date have shown positive patient outcomes with whole-body hyperthermia treatment.

Ovarian Cancer Trial

Our ovarian cancer trial resulted in significant findings on the positive impacts of HEATT®. Patients overall experienced improved survival rates and daily living satisfaction.

Lung Cancer Trial

Verthermia® trial patients with unresponsive lung cancer exceeded average life expectancy after receiving HEATT®.

Intellectual Property

The system and methods of Verthermia® are protected by four issued US patents (11,065,379; 11,185,622; 11,191,883, and 11,239,551). Two other US patent applications are in process, and one international or PCT (Patent Cooperation Treaty) application is in process. Verthermia® has two registered US trademarks, and two other US trademark applications are in process. Verthermia has also filed an application for an international trademark. We have a robust intellectual property policy, and Verthermia® protects some of its proprietary methods as trade secrets. All documents, procedures, websites, and presentations are copyrighted by Verthermia®. Roger and Jan are co-inventors of the CORE-HFC® device which delivers HEATT®.
CONTACT US Today
Verthermia® provides Hyperthermic Extracorporeal Applied Tumor Therapy (HEATT®) to patients with advanced tumors that are unresponsive to traditional cancer treatments.

Follow US:

Facebook Twitter Instagram

Menu

Contact Us

2023 Verthermia
Website Design, Development & SEO by Cardinal Digital Marketing